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Abstract
Background Oral mucositis is a debilitating consequence of radiotherapy in patients with head and neck cancers. Radiation-
induced oral mucositis (RIOM) can cause pain and weight loss, reduce quality of life and affect treatment outcomes.
Methods A systematic review was undertaken to identify and examine the efficacy of low-cost interventions to mitigate RIOM
and to develop clinical guidelines based on the evidence.
Results The author identified three interventions: benzydamine hydrochloride mouth rinse (BHM), honey and oral glutamine
(OG). The search identified twenty-four studies in total. Four studies examined BHM; all findings were favourable, although only
one had moderate methodological quality, and the rest were low. The product was poorly tolerated by some participants in one
study. Twelve studies examined honey. Eleven of these had favourable results; two studies had moderate methodological quality,
and the rest were low. Eight studies examined OG. Six of these had favourable results; two studies had moderate methodological
quality, and the rest were low.
Conclusion The author cannot recommend BHM to mitigate RIOM due to the overall low quality of the studies and poor
tolerance to the product. The author cannot recommend honey to mitigate RIOM due to weak evidence supporting the interven-
tion. The author can recommend OG to mitigate RIOM. There is a need for high-quality studies with a consensus of the
methodology to reduce heterogeneity and examination of the cost-effectiveness of the interventions.
Keywords Radiotherapy . Radiation therapy . Head and neck cancer . Oral mucositis
Introduction
Oral mucositis (OM) is a painful condition, characterised by
ulcers [1]. Rapid cell division in the oral tract makes mucosal
cells particularly sensitive to damage by irradiation [2]. OM
commonly occurs in head and neck cancer patients (HNCPs)
who have had radiotherapy (RT). It can affect up to 100% of
HNCPs [3], and it is therefore a significant problem for this
group. Radiation-induced oral mucositis (RIOM) can have a
detrimental effect on patients’ functioning and quality of life
(QoL): The painful inflammation and ulceration may affect
patients’ ability to eat, drink and talk [4]. It may cause nutri-
tional deficiencies affecting patients’ energy which can cause
weight loss [4]. If severe RIOM occurs, it can affect patients’
health outcomes due to missed radiotherapy treatments; in
fact, RIOM is the most likely side effect of RT to the oral
region, causing limited RT doses [5].
The model for OM pathogenesis includes five stages: first-
ly, direct cell damage to the DNA, followed by tissue damage
to the submucosa and basal epithelium, leading to inflamma-
tion then ulceration of the tissue (where bacteria then cause
even more inflammation) and healing as the final stage [6].
Grade 1 RIOMgenerally starts after approximately 2weeks
of RT, with grade 3 RIOM generally occurring after approx-
imately 3 weeks. Commonly, RIOMpeaks 2 weeks after treat-
ment is completed and is resolved 8 weeks after that [7].
Effective interventions are essential to mitigate RIOM; im-
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National guidelines for oral care for patients at risk of OM
were determined by two organisations in the United Kingdom
(UK): the UK Oral Mucositis in Cancer Group (UKOMCG),
updated in June 2019, and the Royal College of Surgeons of
England and the British Society for Disability, updated in
2018. However, it is unclear how these organisations selected
the studies on which they based their recommendations. Also,
some of these studies were not contemporaneous. The search
for contemporaneous studies in this review identified fifty-
eight interventions for the management of RIOM in the last
5 years. For the majority of the interventions, there were few
studies conducted with small sample sizes making it difficult
to establish efficacy.
National Institute for Health and Clinical Excellence (NICE)
guidelines, published in May 2018, recommended low-level
laser therapy (LLLT) as an effective intervention for OM.
However, the implementation of this intervention in a service
may incur high set-up costs for equipment and training of staff.
Therefore, this study focussed on examining the efficacy of
low-cost interventions, which incur no set-up costs.
The aim of this study was to conduct a systematic review
(SR) of contemporaneous studies to examine the efficacy of
low-cost interventions to mitigate RIOM.
Methods
Study design
The study was designed to establish the efficacy of interven-
tions to mitigate RIOM in HNCPs undergoing RT through a
SR of contemporaneous evidence.
Eligibility criteria
Inclusion criteria
Studies that fitted the following criteria were included:
& Randomised controlled trials (RCTs), SRs and meta-
analyses (MAs)
& Patients receiving RT, with or without chemotherapy
(CT), for head and neck cancers
& Interventions where there had been four or more studies
conducted
& Studies conducted in the last 5 years (from 2014 to 2019)
& Studies in English language
& Studies of adults
Exclusion criteria
Studies were excluded if they fitted the following criteria:
& Studies where full text was not available
& Studies where the interventions had added costs for equip-
ment and training
Search strategy
The search for literature was conducted using the following
databases: Amed, CINHL, Cochrane Library, EMBASE,
EMCARE, Google Scholar, Medline via ovid and PubMed.
The reference lists of the identified studies were also exam-
ined to find additional studies that fit the criteria that were not
found through the database search.
Keywords used in the search were “Radiotherapy” or “ra-
diation therapy” and “oral mucositis” or “mucositis”. The fol-
lowing Boolean operators were utilised: AND and OR.
Figure 1 shows the search strategy adopted in this SR.
Outcomes
The primary outcome measure was OM grade using any ap-
propriate assessment scale, recorded in any format (for
Fig. 1 Flow chart showing the search strategy adopted in this review
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example incidence of severe OM, onset of OM, duration of
OM) or OM pain (measured using a visual analogue scale or
numerical rating scale). The following OM assessment tools
were identified: World Health Organization (WHO) OM as-
sessment tool; Radiation Therapy Oncology Group (RTOG)
OM grading system; Oral Mucositis Assessment Scale
(OMAS) and the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI CTCAE).
All secondary outcome measures were included.
Assessment of methodological quality and quality of
evidence
The studies’ methodologies were appraised utilising Critical
Appraisal Skills Programme (CASP) checklist for RCTs and
SRs and recorded on Excel sheets. The quality of the evidence
for all studies was assessed using Harbour andMiller’s (2001)
Hierarchy of Evidence. The assessments were conducted by
the author.
Data collection
Data from the studies was collected and recorded on
standardised Excel forms by the author. The data extracted
included author, year, title, aim of the study, study design,
sample size, inclusion and exclusion criteria, randomisation
method, intervention, control, details of cancer treatment, pri-
mary and secondary outcome measures, results and
conclusion.
Risk of bias across studies
The author considered the risk of bias across the studies.
Translation of results into clinical guidelines
The findings of the review were applied to the GRADE
Evidence to Decision (EtD) framework [8] to inform clinical
guidance for the mitigation of RIOM.
Results
Study selection
Initially, the search identified 1508 studies. One thousand four
hundred eighty-six studies were excluded because they did not
meet the set criteria or were duplications. A search of refer-
ence lists identified two more studies. In total, twenty-four
studies met the inclusion criteria.
Study characteristics
A summary of the studies’ characteristics and results are in
Tables 1 and 2.
The interventions identified, where there were at least four
studies, were benzydamine hydrochloride mouth rinse (BHM;
RCT, n = 4), honey (SR or MA, n = 6; RCT, n = 6) and oral
glutamine (OG; SR or MA, n = 2; RCT, n = 6). A total sample
size for each intervention was BHM (n = 311), honey (n =
more than 3985) and OG (n = 924).
Five out of the 16 RCTs used a placebo as control. Other
controls used were standard care (n = 4), saline (n = 3),
povidone iodine rinse (n = 2), sodium bicarbonate (n = 1)
and water (n = 1). The most commonly used OM assessment
tool was the RTOG OM assessment tool (n = 10) followed by
WHO OM assessment tool (n = 9) and NCI CTCAE (n = 9)
then OMAS (n = 4). One study utilised a non-validated OM
assessment tool; two RCTs utilised more than one validated
OM assessment tool; and one study did not describe how OM
was assessed.
OMwas presented in twelve ways: incidence of severe OM
(n = 18), onset of OM (n = 9), mean OM grade (n = 4), mean
maximum OM grade (n = 4), duration of OM (n = 3), inci-
dence of OM (n = 3), reduction of OM (n = 2), median OM
(n = 1), OM recovery time (n = 1), number of OM lesions (n =
1), functional OM (n = 1), mucositis grade at 1 week (n = 1).
Twenty-nine secondary outcomes were measured. The most
common were pain (n = 10), weight loss (n = 8), treatment
interruptions (n = 8), number of patients requiring feeding
tubes (n = 5), number of patients requiring analgesia use
(n = 4) and quality of life (n = 4). The least commonly utilised
secondary outcomes measured by only one of the identified
studies were number of patients requiring IV fluids, artificial
saliva or anti-infection interventions; number of patients who
developed dysphagia, nausea, cough or oedema; duration of
opioid use; vital signs; blood counts; electrolytes; and renal
function.
Synthesis of results
Benzydamine hydrochloride mouth rinse
Primary outcome measure (oral mucositis measures) Two out
of the four studies [9, 10] measured incidence of severe
(grades 3 and 4) OM. Both found a statistically significant
reduction in severe OM in the BHM group. One study [11]
measured the mean OM grade and found a statistically signif-
icant reduction in the BHM group in weeks 4 to 7 of RT. One
study [12] measured the median OM and found a statistically
significant reduction in the BHM group. The same study mea-
sured the mean maximum OM grade and found a lower OM
grade in the BHM group; the statistical significance was not
calculated.
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Secondary outcome measures Three studies measured treat-
ment interruptions; one study [10] found statistically signifi-
cantly fewer treatment interruptions in the BHM group receiv-
ing RT alone but not in the group receiving chemoradiother-
apy (CRT). One study [11] found fewer treatment interrup-
tions but did not calculate statistical significance, and one
study [12] found no statistically significant difference between
the groups. Two studies measured the number of participants
who required feeding tubes fitted. One study [10] found sta-
tistically significantly fewer participants in the BHM group,
receiving RT alone, required feeding tubes fitted. They found
no statistically significant difference between the groups re-
ceiving CRT. The second study [12] did not find a statistically
significant difference between the groups.
Only one study [12] recorded adverse events (AEs) and
found that 6.75% of participants in the BHM group were
unable to tolerate the full strength of BHM due to a burning
sensation in the mouth.
Quality of studies A summary of the critical appraisal of the
RCTs is in Table 3 and SRs and MAs in Table 4.
The overall methodological quality of three out of the four
studies examining the use of BHM to mitigate RIOM was
low. Only one study [12] had moderate methodological
quality.
Honey
Primary outcome measure (oral mucositis measures)Nine out
of the twelve studies measured the incidence of severe OM.
Seven of these studies [13–19] found statistically significantly
fewer patients in the honey group had severe OM; the other
two studies [20, 21] found no statistically significant differ-
ence between the groups. Four studies [16–18, 21] measured
onset of OM. All found onset of OMwas delayed in the honey
group although only the first three calculated statistical signif-
icance. Two studies measured the mean OM grade; one study
[13] found a statistically significant lower mean grade of OM
during the second 3 weeks of RT; the other study [17] found a
lower mean OM score but did not calculate the statistical
significance. Two studies measured the difference in OM
grade between the intervention and control groups. One study
[22], a SR, reviewed 17 studies and found a lower OM grade
in the honey group in 12 out of the 17 studies; the other study
[19] found no statistically significant difference between the
groups. One study [23] measured incidence of OM and found
a statistically significant lower incidence of OM over the
course of treatment. One study [19] measured the number of
OM lesions and found statistically significantly fewer OM
lesions in the honey group.
Secondary outcome measures Six studies measured pain.
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significantly lower pain scores in the honey group; one SR
[22] reported that four out of the five studies it reviewed found
lower pain scores in the honey groups; two studies [13, 20]
found no statistically significant difference in pain scores be-
tween the groups.
Six studies measured weight loss. Four studies [13, 16, 17,
21] found statistically significant less weight loss in the honey
groups; one SR [22] found less weight loss in the honey
groups in the studies it reviewed, and one study [20] found
no statistical significant difference between the groups.
Three studies [16, 21, 22] measured RT interruptions. All
found fewer RT interruptions in the honey groups; the former
two studies had statistically significant findings, and the latter
did not calculate statistical significance.
Four studies measured QoL; three studies [17, 19, 22]
found higher QoL scores in the honey group but only one of
those [17] calculated the statistical significance. The fourth
study [20] found no statistically significant difference between
the groups.
Three studies recorded AEs: one study [20] found most of
the participants who dropped out of the study reported nausea,
a strong taste of honey or burning in the mouth. One study
[13] reported AEs but it is more likely these were related to the
OM itself rather than the product. One study [18] reported that
there were no AEs related to honey.
Quality of studies Only two out of the twelve studies [18, 21]
investigating the use of honey tomitigate RIOMhadmoderate
methodological quality. The other ten had lowmethodological
quality.
Oral glutamine
Primary outcome measure (oral mucositis measures) Seven
out of the eight studies examining OG [25–31] measured in-
cidence of severe OM. All but one study [25] found statisti-
cally significantly fewer patients in the OG group had severe
OM. Five studies measured onset of OM. Three of these stud-
ies [26, 29, 30] found a statistically significant delay in onset
of OM in the OG group; the other two studies [27, 32] found
no statistically significant difference between the groups.
Three studies [25, 27, 29] measured maximum OM scores
with all finding statistically significantly lower maximum
OM score in the OG groups. Three studies measured duration
of OM; one study [26] found a statistically significant shorter
duration of OM in the OG group; one study [27] found no
statistically significant difference, and one SR [29] reviewed
two studies, one of which found a statistically significant dif-
ference and the other did not. One study [32] measured inci-
dence of OM (grades 1 to 4) and found no statistically signif-
icant difference between the groups. One study [27] measured
meanOM and found a statistically significant lower meanOM
score in the OG group during weeks 5 and 6 of RT. One study
[32] measured functional OM and found no statistically sig-
nificant difference between the groups.
Secondary outcome measures Four studies measured pain;
two of those studies [27, 29] found a statistically significant
reduction in pain in the OG group; one study [30] found fewer
participants in the OG group experienced pain although the
statistical significance was not reported; one study [32] found
no statistically significant difference between the groups.
Three studies measured the number of participants requir-
ing analgesics. One of those studies [27] found no statistically
significant difference; one SR [29] reviewed a study which
found no difference; and one study [30] found fewer partici-
pants in the OG group required analgesics, although the sta-
tistical significance was not reported.
Three studies measured weight loss. One SR [29] reviewed
two studies, one of which found statistically significantly less
weight loss in the OG group and the other did not; one study
[32] found no statistically significant difference between the
groups; and one study [31] found statistically significantly less
weight loss in the OG group.
Three studies [29–31] measured the number of participants
requiring feeding tubes. All found fewer patients in the OG
group required feeding tubes fitted, although only the former
two reported that the findings were statistically significant.
Four studies recorded AEs. Three studies [27, 29, 32] re-
ported no AEs related to OG. One study [30] reported more
AEs in the control group, but it was likely these were related to
OM rather than the product.
Quality of studies Two studies [25, 28] had moderate meth-
odological quality. The other six studies had low methodolog-
ical quality.
Risk of bias across studies The author considered that the risk
of bias across the studies was high due to heterogeneity.
Recommendations for clinical practice
The GRADEEvidence to Decision framework [8] was used to
assess the evidence from this SR. A summary of the judge-
ments and conclusions for interventions to mitigate RIOM in
HNCPs are outlined in Tables 5 and 6.
Although the findings in the studies examining BHMwere
mainly positive, the author cannot recommend BHM to miti-
gate RIOM due to the overall low methodological quality and
poor tolerance of the product.
Eleven out of the twelve studies examining honey found it
to be efficacious either in reducing the incidence of severe OM
or mean OM grade, or delaying onset of OM. Additionally, of
those eleven studies, two were of moderate methodological
quality. However, one of the studies with moderate methodo-
logical quality [21] found honey to be efficacious at delaying
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onset of OM (and reducing RT interruptions and weight loss)
but not at reducing OM severity. Therefore, the author can
only recommend honey to reduce complications of RIOM,
but not to mitigate it. Three out of the six RCTs included
patients having moderate doses of RT, and so the author can-
not recommend this intervention for patients having higher
doses of RT (at least 64 Gy). Additionally, there is a potential
risk of honey consumption in diabetic patients. Finally, the
author cannot recommend Manuka honey due to the poor
tolerance.
Seven out of the eight studies examining the use of OG to
mitigate RIOM had favourable findings. Two studies were of
moderate methodological quality, and there were no adverse
effects recorded. So, the author can recommend OG to miti-
gate RIOM.
Discussion
This systematic review examined the efficacy of low-cost in-
terventions to mitigate RIOM. The review identified interven-
tions where there had been four or more studies examining it,
conducted within the last 5 years. These interventions were
BHM, honey and OG. The search identified twenty-four stud-
ies. The efficacies of the interventions were examined through
the assessment of OM and secondary outcome measures. The
review examined the interventions’ safety through the collec-
tion of data on adverse effects encountered. Following this,
the evidence was applied to the GRADE EtD frameworks to
inform clinical guidelines.
Recurrent themes that emerged included small sample
sizes, most RCTs being single-centre studies, lack of blinding,
heterogeneity, lack of data on AEs and lack of analysis of
cost-effectiveness.
Most of the RCTs were small, single-centre studies, and
even the two multi-centre studies had small sample sizes.
Small samples are at risk of false-negative findings, and
single-centre studies limit generalisability. Few of the studies
examined in this review were blinded and those that were not
risk bias. Also, in the blinded studies examining honey, the
distinct taste and consistency of honey possibly increased the
risk of performance bias. Identification of an effective placebo
is necessary for well-conducted blinding and to reduce the risk
of bias.
There was significant heterogeneity identified in the studies
making it difficult to draw robust conclusions. Areas where
heterogeneity was identified include OM assessment tools
used, presentation of OM data, secondary outcome measures,
doses and frequency of intake of the interventions, type of
honey used, cancer treatments delivered (including patients
receiving RT alone, CRT alone, or RT or CRT; type of RT
machines; RT techniques—such as conventional or IMRT,
and RT dose) and inclusion of certain cancer types. To reduce
heterogeneity, the author recommends consensus of a meth-
odology to be used in future studies.
Four OM assessment tools were identified. Although use of
different OM assessment tools may introduce heterogeneity,
one study [20] found good inter-reliability between RTOG,
WHO and OMAS.
Overall, OM data was presented in twelve ways (for exam-
ple data was presented as severity of OM, incidence of OM
and onset of OM), and twenty-nine secondary outcomes were
recorded, which introduced heterogeneity into the studies. The
most common ways that OM data was presented was as inci-
dence of severe OM and onset to OM; the most common
secondary outcome measures used were pain, weight loss
and RT interruptions. So, the author recommends that future
studies present data in these ways and use the aforementioned
secondary outcome measures.
The dose and frequency of consumption of the products
varied which also introduced heterogeneity. The author rec-
ommends that studies examining the optimum dose be con-
ducted. The type of honey used in the studies introduced fur-
ther heterogeneity. One study [20] used Manuka honey, an-
other [17] used thyme honey and the others used locally
sourced, or pure, honey. Pooling data from studies using dif-
ferent types of honey may compromise the findings since
some types of honey may be more effective at mitigating
RIOM than others. One MA [21] found that the type of honey
did not confound the findings; another MA [18] found local
and pure natural honey efficacious and Manuka honey not
efficacious at mitigating RIOM. An SR [22] reviewed thirteen
studies which found conventional honey to be efficacious and
four studies which found Manuka honey not to be efficacious.
Three BHM studies and three honey studies included par-
ticipants having moderate doses of RT (between 50 and
64 Gy). It is likely that OM is less severe in patients having
lower RT doses, and there is a possibility that including pa-
tients on lower doses makes the findings more favourable.
Therefore, the findings can only be cautiously applied to pa-
tients having higher doses of RT.
There was additional heterogeneity due to inclusion of pa-
tients having different types of cancer treatment: either RT
alone, CRT alone, or RT or CRT. Two studies [10, 13] found
that BHM only mitigated RIOM in patients having RT alone,
not in those having CRT; and two studies [18, 26] found the
intervention efficacious for patients having either RT or CRT.
Therefore, the author recommends future research examining
the efficacy of the interventions for each cancer treatment
option.
There was further heterogeneity in the types of radiothera-
py delivered. Some studies included patients having treatment
on cobalt machines, or conventional RT, where it is likely that
RIOM is greater, due to larger margins required for the treat-
ment field. Other studies included patients having intensity-
modulated RT (IMRT) which treats smaller margins, and so
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RIOM is likely to be less severe. Two out of the six OG
RCTs [25, 31] only included patients having IMRT.
However, there were favourable results in the OG RCT
[30] using conventional RT and in the OG MA [28], which
had moderate methodological quality, which included pa-
tients having treatment using any type of RT technique.
However, more research is needed to understand if RT tech-
niques are confounding factors.
Although eight studies measured acute AEs [12, 13, 18,
20, 27, 29, 30, 32], none measured long-term AEs. One may
assume that, due to the sugar content, prolonged consump-
tion of honey can induce dental caries. However, a recent
study [33] found that honey can prevent dental caries. The
high sugar content makes honey unsuitable for long-term
consumption by diabetic patients [34]. This contraindication
was considered by four of the honey studies [13, 14, 16, 17]
which excluded people with diabetes from participating, and
another study [20] where participants were asked to monitor
their blood sugar levels. However, excluding diabetic pa-
tients reduces generalisability of the findings. An RCT ex-
amining the use of parenteral alanyl-glutamine dipeptide,
used as a supplement for autologous bone marrow transplant
patients [35], found an increased mortality rate in the inter-
vention group. However, a more recent SR and MA [36]
reviewing glutamine supplementation for haematopoietic
stem cell transplantation found no effect of either oral or
IV glutamine on mortality rates. The author recommends
future studies that examine the long-term AE of the
interventions.
A significant limitation of the studies included in the SR
was the quality of the methodologies. The methodologies of
only five out of the twenty-four studies identified were of
moderate quality. It is likely that the internal validity of low-
quality studies may be compromised, and it is, therefore,
difficult to draw robust conclusions. Therefore, it is recom-
mended that future studies continue to improve the quality of
the methodologies.
The focus of this review was to examine low-cost inter-
ventions to mitigate RIOM. Low-cost interventions were
classed as those with few set-up costs. However, none of
the studies examined the cost-effectiveness of the interven-
tions, and so the author cannot make strong recommenda-
tions based on this. The author recommends future research
in this area. The author acknowledges that there are financial
barriers to producing high-quality research on low-cost in-
terventions. Until more high-quality studies are available,
the author recommends that clinicians consider the best
available evidence-based interventions.
There were some limitations in the methodology of this
SR. One limitation was that the search for studies was not
comprehensive. The search only included studies in English
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lished studies. So, it is likely that selection and publication
bias was present.
The author included interventions where there had been at
least four studies conducted. Most studies examining RIOM
have small sample sizes and are of lowmethodological quality
and so risk false-negative findings. Including interventions
with four or more studies reduces this risk, and so more robust
conclusions could be drawn. However, including interven-
tions where there had been fewer, good-quality studies may
have been more appropriate. The author excluded studies con-
ducted more than 5 years ago so that only the most up-to-date
studies were included. However, selection bias could have
been reduced by not limiting the search by year of publication.
Another limitation was that the SR only examined low-cost
interventions. When making recommendations for clinical prac-
tice, the primary aim should be to find efficacious interventions
over cost-saving ones. An alternative approach to research in this
area could be to find cost-saving methods for already-established
interventions for RIOM. For example, finding lower cost LLLT
devices, finding ways to reduce training costs or having regional
centres delivering LLLT (to reduce the number of devices need-
ed and number of people trained to deliver the treatment).
A further limitation of this SR was that the research was
conducted by one person, which may introduce bias. Finally,
the SR only examined the efficacy of interventions to mitigate
RIOM, and so conclusions cannot be applied to other causes
of OM.
Conclusion
The author cannot recommend the BHM to mitigate RIOM
due to the low quality of the studies and poor tolerance to the
product. The author cannot recommend honey to mitigate
RIOM but can recommend it to reduce complications of
RIOM (for example weight loss, pain, RT interruptions) for
patients on moderate doses of RT but not for diabetic patients.
The author can recommend OG to mitigate RIOM. There is a
need for high-quality studies with a consensus of the method-
ology to reduce heterogeneity and examination of the cost-
effectiveness of the interventions.
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